<DOC>
	<DOCNO>NCT01668823</DOCNO>
	<brief_summary>This phase I trial study side effect best dose photodynamic therapy use HPPH treat patient lung cancer . Photodynamic therapy use drug , HPPH , become active expose certain kind light . When drug active , cancer cell kill .</brief_summary>
	<brief_title>Photodynamic Therapy Treating Patients With Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerate light dose ( MTID ) . Identify systemic normal tissue toxicity use 2- [ hexyloxyethyl ) -2-devinyl pyropheophorbide-a ( HPPH ) photodynamic therapy patient bronchogenic carcinoma-in-situ ( CIS ) microinvasive carcinoma . SECONDARY OBJECTIVES : I . To study tumor response patient bronchogenic carcinoma-in-situ ( CIS ) bronchogenic microinvasive carcinoma . OUTLINE : This dose-escalation study . Patients receive HPPH intravenously ( IV ) 1 hour day 1 . Patients photodynamic therapy laser light day 3 . Patients also undergo therapeutic bronchoscopy endoscopic debridement day 5 . After completion study treatment , patient follow 4-6 week , 6 month , periodically least 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Patients biopsy confirm carcinomainsitu ( CIS ) microinvasive lung cancer Patients may squamous cell carcinoma , adenocarcinoma , large cell carcinoma Patients may receive prior therapy lung cancer type , e.g . chemotherapy , radiation therapy Patients must contraindications bronchoscopy Female patient must pregnant must practice medically acceptable form birth control , sterile postmenopausal Patients must Karnofsky scale 50 ( Eastern Cooperative Oncology Group [ ECOG ] 02 ) Patients must sign Informed Consent accord Food Drug Administration ( FDA ) guideline acceptable Roswell Park Cancer Institute ( RPCI ) Institutional Review Board ( IRB ) Patients underlie lung disease must judge ( principal investigator ) able stand mucous/debris formation site treatment Definition CIS microinvasive lung cancer protocol : lesion radiographically occult definable conventional compute tomography ( CT ) chest ; lesion may may invisible white light bronchoscopy , definable photographable lung image fluorescence endoscope ( LIFE ) bronchoscopy ; biopsy lesion must indicate evidence invasion beyond cartilage histopathology ; lesion may , however , invasive basement membrane ( microinvasive carcinoma ) Porphyria hypersensitivity porphyrin porphyrinlike compound White blood cell ( WBC ) &lt; 4000 Platelet count &lt; 100,000 Prothrombin time exceed 1.5 time upper normal limit Total serum bilirubin &gt; 3.0 mg/dl Serum creatinine &gt; 3.0 mg/dl Alkaline phosphatase ( hepatic ) serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 3 time upper normal limit Severe chronic obstructive pulmonary disease ( COPD ) would opinion investigator preclude multiple bronchoscopies partial central airway obstruction mucous/debris formation Any evidence worsen pulmonary symptom COPD exacerbation Evidence major pulmonary vessel encasement CT scan chest Myocardial infarction ( Ml ) unstable angina previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>